Ionis PharmaceuticalsIONS
About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Employees: 927
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
53% more call options, than puts
Call options by funds: $38M | Put options by funds: $24.8M
18% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 108
0.45% less ownership
Funds ownership: 99.06% [Q2] → 98.61% (-0.45%) [Q3]
2% less funds holding
Funds holding: 353 [Q2] → 347 (-6) [Q3]
10% less capital invested
Capital invested by funds: $6.89B [Q2] → $6.22B (-$669M) [Q3]
10% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 58
50% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 3 (-3) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Needham Joseph Stringer 26% 1-year accuracy 33 / 127 met price target | 64%upside $60 | Buy Maintained | 20 Dec 2024 |
Piper Sandler Allison Bratzel 82% 1-year accuracy 9 / 11 met price target | 70%upside $62 | Overweight Maintained | 14 Nov 2024 |
Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 17 met price target | 111%upside $77 | Overweight Maintained | 7 Nov 2024 |
Guggenheim Debjit Chattopadhyay 40% 1-year accuracy 8 / 20 met price target | 78%upside $65 | Buy Maintained | 9 Oct 2024 |
RBC Capital Luca Issi 23% 1-year accuracy 13 / 56 met price target | 92%upside $70 | Outperform Reiterated | 26 Sept 2024 |
Financial journalist opinion
Based on 7 articles about IONS published over the past 30 days